Literature DB >> 16891051

Long-term results of tension-free vaginal tape (TVT) for the treatment of female urinary stress incontinence.

G Chêne1, J Amblard, A S Tardieu, J R Escalona, A Viallon, B Fatton, B Jacquetin.   

Abstract

OBJECTIVES: Prospective evaluation of outcome and complications over a 5-year period post-treatment of urinary stress incontinence by TVT, and comparison of our results with the reference studies.
MATERIALS AND METHODS: About 94 patients were treated for urinary stress incontinence only by one TVT procedure (single surgical procedure), between April 1997 and December 1998; 68% of patients presented pure urinary stress incontinence and 32% mixed incontinence. We found also a 25.5% rate of sphincter deficiency (UCP < 20 cm H(2)O) in this cohort. Patients were evaluated after 5 years: 52 complete evaluations (clinical, flow measurement with measurement of post-mictional residue, 24h PAD-test, quality of life questionnaire), 30 complete telephone interviews, 12 lost to follow-up (2 patients deceased).
RESULTS: About 87% of the patients had a 5-year follow-up. The success rate was 79.2% overall (84.5% for the pure urinary stress incontinence and 67% for the mixed incontinence cases), and 72.2% for the cases of associated sphincter deficiency. We had only a 13% rate of patients lost to follow-up. More than half of the urinary urgency cases were treated successfully, however with a less satisfactory outcome in cases of bladder instability. The urodynamic exploration appeared to reveal that TVT caused dysuria: 52% of patients had a maximum flowrate below 15 ml/s, but the quality of life was improved, with a 95% rate of satisfaction without functional problems. We observed no late complications such as vaginal erosion or rejection of the prolene; the de novo syndrome was rare, with 8.5% of urinary frequency, 6% of urinary urgency and only 5.7% of invalidating dysuria. We saw no cases of pelvic floor disease after TVT treatment. DISCUSSION: Our casuistry results are comparable with the reference studies by Scandinavian authors, Rezapour and Ulmsten, confirming the long-term success of the TVT procedure. Concerning the apparently elevated rates of post-TVT dysuria found by urodynamic exploration, a distinction has to be drawn between post-TVT urinary problems (frequent but oligosymptomatic), and true, severe dysuria (rare). However, "dysuria" in the broad sense did not affect the patients' quality of life, and is a reminder of the absolute necessity of meticulous compliance with the correct surgical techniques.
CONCLUSION: Treatment of urinary incontinence by TVT is a reliable, mini-invasive, reproducible technique, almost suitable for outpatients, with no serious complications; it is inexpensive and very successful, including in complicated cases such as sphincter deficiency. All the recent data confirms, with this 5-year follow-up, that the TVT procedure is comparable to the previously gold standard, the Burch colposuspension.

Entities:  

Mesh:

Year:  2006        PMID: 16891051     DOI: 10.1016/j.ejogrb.2006.06.009

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  24 in total

1.  Long-term subjective results of tension-free vaginal tape operation for female urinary stress incontinence.

Authors:  Karin Glavind; Emilie Glavind; Morten Fenger-Grøn
Journal:  Int Urogynecol J       Date:  2011-11-18       Impact factor: 2.894

Review 2.  Do urodynamic parameters predict persistent postoperative stress incontinence after midurethral sling? A systematic review.

Authors:  Amie Kawasaki; Jennifer M Wu; Cindy L Amundsen; Alison C Weidner; John P Judd; Ethan M Balk; Nazema Y Siddiqui
Journal:  Int Urogynecol J       Date:  2012-03-09       Impact factor: 2.894

3.  Identification of the optimal time to treat urgency after a midurethral sling procedure for stress urinary incontinence.

Authors:  Cheryn Song; Sang Hyun Park; Ji Yeon Han; Kyu-Sung Lee; Myung-Soo Choo
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-10-02

4.  TVT-S for surgical treatment of stress urinary incontinence: prospective trial, 1-year follow-up.

Authors:  Ladislav Krofta; Jaroslav Feyereisl; Petr Velebil; Michal Otcenásek; Eva Kasíková; Michal Krcmár
Journal:  Int Urogynecol J       Date:  2010-04-01       Impact factor: 2.894

Review 5.  Outcome measures and definition of cure in female stress urinary incontinence surgery: a survey of recent publications.

Authors:  Peter A Castillo; Luis M Espaillat-Rijo; G Willy Davila
Journal:  Int Urogynecol J       Date:  2010-01-06       Impact factor: 2.894

6.  [Tethered tape or the fourth factor. A new cause of recurrent stress incontinence after midurethral tape procedures vaginal tape insertion].

Authors:  J Kociszewski; G Fabian; S Grothey; V Viereck; I Füsgen; A Wiedemann
Journal:  Urologe A       Date:  2014-01       Impact factor: 0.639

7.  TVT and TVT-O for surgical treatment of primary stress urinary incontinence: prospective randomized trial.

Authors:  Ladislav Krofta; Jaroslav Feyereisl; Michal Otcenásek; Petr Velebil; Eva Kasíková; Michal Krcmár
Journal:  Int Urogynecol J       Date:  2009-11-12       Impact factor: 2.894

8.  Pelvic floor consequences of cesarean delivery on maternal request in women with a single birth: a cost-effectiveness analysis.

Authors:  Xiao Xu; Julie S Ivy; Divya A Patel; Sejal N Patel; Dean G Smith; Scott B Ransom; Dee Fenner; John O L Delancey
Journal:  J Womens Health (Larchmt)       Date:  2010-01       Impact factor: 2.681

9.  Long-term durability, functional outcomes, and factors associated with surgical failure of tension-free vaginal tape procedure.

Authors:  Ji-Yeon Han; Junsoo Park; Myung-Soo Choo
Journal:  Int Urol Nephrol       Date:  2014-06-18       Impact factor: 2.370

Review 10.  Safety considerations for synthetic sling surgery.

Authors:  Jerry G Blaivas; Rajveer S Purohit; Matthew S Benedon; Gabriel Mekel; Michael Stern; Mubashir Billah; Kola Olugbade; Robert Bendavid; Vladimir Iakovlev
Journal:  Nat Rev Urol       Date:  2015-08-18       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.